Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Akio Katanuma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3548-5215; OpenAlex author ID A5004472078, A5058232958. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 15

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. A rare case of immunoglobulin G4-related periarteritis mimicking pancreatic cancer. Co-author DOI 10.1007/s12328-025-02250-8↗
  3. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  4. Early Detection of Pancreatic Adenocarcinoma Using Triple-phase contrast-enhanced Computed Tomography: A Case-control Study. Last author DOI 10.1097/mpa.0000000000002712↗
  5. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  6. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  7. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  8. [The roll of endoscopy for the differentiating between distal bile duct cancer and pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.119.1061↗
  9. Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable … Co-author DOI 10.1136/bmjopen-2020-045698↗
  10. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… Co-author DOI 10.5009/gnl19302↗
  11. Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration for patients undergoing distal pancreatectomy for pancrea… Last author DOI 10.1111/den.13615↗
  12. [Diagnosis of resectable pancreatic cancer]. First author DOI 10.11405/nisshoshi.117.290↗
  13. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗
  14. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  15. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 3 shared papers, 2019–2025 · strength 0.39
  2. Masato Ozaka · 3 shared papers, 2017–2025 · strength 0.38
  3. Tsuyoshi Hayashi · 2 shared papers, 2019–2026 · strength 0.36
  4. Hajime Yamazaki · 2 shared papers, 2019–2026 · strength 0.36
  5. Shinichi Hashimoto · 2 shared papers, 2021–2026 · strength 0.35
  6. Hiroshi Nakase · 1 shared paper, 2026 · strength 0.33
  7. Kazunori Onuma · 1 shared paper, 2026 · strength 0.33
  8. Satoshi Kobayashi · 2 shared papers, 2023–2025 · strength 0.32
  9. Masafumi Ikeda · 2 shared papers, 2023–2025 · strength 0.32
  10. Yukiko Takayama · 2 shared papers, 2023–2025 · strength 0.32
  11. Akiko Todaka · 2 shared papers, 2023–2025 · strength 0.32
  12. Akihiro Ohba · 2 shared papers, 2023–2025 · strength 0.32
  13. Junji Furuse · 2 shared papers, 2023–2025 · strength 0.32
  14. Nao Fujimori · 2 shared papers, 2023–2025 · strength 0.32
  15. Kentaro Sudo · 2 shared papers, 2019–2026 · strength 0.31
  16. Kazuo Hara · 2 shared papers, 2019–2026 · strength 0.31
  17. Masayuki Kitano · 2 shared papers, 2019–2026 · strength 0.31
  18. Yasuo Sakurai · 1 shared paper, 2026 · strength 0.29
  19. Makoto Yoshida · 3 shared papers, 2019–2021 · strength 0.28
  20. Kousuke Iwano · 1 shared paper, 2022 · strength 0.26
  21. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.24
  22. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.24
  23. Noboru Ideno · 1 shared paper, 2026 · strength 0.24
  24. Kenoki Ohuchida · 1 shared paper, 2026 · strength 0.24
  25. Yasuhisa Mori · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.